Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

SRx Health Solutions (SRXH) EBITDA (2016 - 2025)

SRx Health Solutions (SRXH) has disclosed EBITDA for 16 consecutive years, with -$26.9 million as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, EBITDA fell 565.17% year-over-year to -$26.9 million, compared with a TTM value of -$20.0 million through Jun 2025, down 66.7%, and an annual FY2024 reading of $4.2 million, up 119.79% over the prior year.
  • EBITDA was -$26.9 million for Q2 2025 at SRx Health Solutions, down from -$1.1 million in the prior quarter.
  • Across five years, EBITDA topped out at $22.9 million in Q4 2022 and bottomed at -$26.9 million in Q2 2025.
  • Average EBITDA over 5 years is -$2.6 million, with a median of -$3.2 million recorded in 2021.
  • The sharpest move saw EBITDA surged 559.84% in 2022, then plummeted 565.17% in 2025.
  • Year by year, EBITDA stood at -$5.0 million in 2021, then soared by 559.84% to $22.9 million in 2022, then plummeted by 155.59% to -$12.7 million in 2023, then skyrocketed by 171.58% to $9.1 million in 2024, then tumbled by 395.64% to -$26.9 million in 2025.
  • Business Quant data shows EBITDA for SRXH at -$26.9 million in Q2 2025, -$1.1 million in Q1 2025, and $9.1 million in Q4 2024.